Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients.
Peru
central nervous system (CNS)
pediatric
sarcoma
somatic DICER1 mutation
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 Feb 2022
15 Feb 2022
Historique:
revised:
03
09
2021
received:
21
03
2021
accepted:
10
09
2021
pubmed:
22
10
2021
medline:
11
3
2022
entrez:
21
10
2021
Statut:
ppublish
Résumé
A high frequency of primary central nervous system (CNS) sarcomas was observed in Peru. This article describes the clinical characteristics, biological characteristics, and outcome of 70 pediatric patients. Data from 70 pediatric patients with primary CNS sarcomas diagnosed between January 2005 and June 2018 were analyzed. DNA methylation profiling from 28 tumors and gene panel sequencing from 27 tumors were available. The median age of the patients was 6 years (range, 2-17.5 years), and 66 of 70 patients had supratentorial tumors. DNA methylation profiling classified 28 of 28 tumors as primary CNS sarcoma, DICER1 mutant. DICER1 mutations were found in 26 of 27 cases, TP53 mutations were found in 22 of 27 cases, and RAS-pathway gene mutations (NF1, KRAS, and NRAS) were found in 19 of 27 tumors, all of which were somatic (germline control available in 19 cases). The estimated incidence in Peru was 0.19 cases per 100,000 children (<18 years old) per year, which is significantly higher than the estimated incidence in Germany (0.007 cases per 100,000 children [<18 years] per year; P < .001). Patients with nonmetastatic disease (n = 46) that were treated with a combination therapy had a 2-year progression-free survival (PFS) rate of 58% (95% CI, 44%-76%) and a 2-year overall survival rate of 71% (95% CI, 57%-87%). PFS was the highest in patients treated with chemotherapy with ifosfamide, carboplatin, and etoposide (ICE) after upfront surgery followed by radiotherapy and ICE (2-year PFS, 79% [59%-100%], n = 18). Primary CNS sarcoma with DICER1 mutation has an aggressive clinical course. A combination of surgery, chemotherapy, and radiotherapy seems beneficial. An underlying cancer predisposition syndrome explaining the increased incidence in Peruvian patients has not been identified so far. A high incidence of primary pediatric central nervous system sarcomas in the Peruvian population is described. Using sequencing technologies and DNA methylation profiling, it is confirmed that these tumors molecularly belong to the recently proposed entity "primary central nervous system sarcomas, DICER1 mutant." Unexpectedly, DICER1 mutations as well as all other defining tumor mutations (TP53 mutations and RAS-pathway mutations) were not inherited in all 19 patients where analyzation was possible. These tumors have an aggressive clinical course. Multimodal combination therapy based on surgery, ifosfamide, carboplatin, and etoposide chemotherapy, and local radiotherapy leads to superior outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
A high frequency of primary central nervous system (CNS) sarcomas was observed in Peru. This article describes the clinical characteristics, biological characteristics, and outcome of 70 pediatric patients.
METHODS
METHODS
Data from 70 pediatric patients with primary CNS sarcomas diagnosed between January 2005 and June 2018 were analyzed. DNA methylation profiling from 28 tumors and gene panel sequencing from 27 tumors were available.
RESULTS
RESULTS
The median age of the patients was 6 years (range, 2-17.5 years), and 66 of 70 patients had supratentorial tumors. DNA methylation profiling classified 28 of 28 tumors as primary CNS sarcoma, DICER1 mutant. DICER1 mutations were found in 26 of 27 cases, TP53 mutations were found in 22 of 27 cases, and RAS-pathway gene mutations (NF1, KRAS, and NRAS) were found in 19 of 27 tumors, all of which were somatic (germline control available in 19 cases). The estimated incidence in Peru was 0.19 cases per 100,000 children (<18 years old) per year, which is significantly higher than the estimated incidence in Germany (0.007 cases per 100,000 children [<18 years] per year; P < .001). Patients with nonmetastatic disease (n = 46) that were treated with a combination therapy had a 2-year progression-free survival (PFS) rate of 58% (95% CI, 44%-76%) and a 2-year overall survival rate of 71% (95% CI, 57%-87%). PFS was the highest in patients treated with chemotherapy with ifosfamide, carboplatin, and etoposide (ICE) after upfront surgery followed by radiotherapy and ICE (2-year PFS, 79% [59%-100%], n = 18).
CONCLUSIONS
CONCLUSIONS
Primary CNS sarcoma with DICER1 mutation has an aggressive clinical course. A combination of surgery, chemotherapy, and radiotherapy seems beneficial. An underlying cancer predisposition syndrome explaining the increased incidence in Peruvian patients has not been identified so far.
LAY SUMMARY
BACKGROUND
A high incidence of primary pediatric central nervous system sarcomas in the Peruvian population is described. Using sequencing technologies and DNA methylation profiling, it is confirmed that these tumors molecularly belong to the recently proposed entity "primary central nervous system sarcomas, DICER1 mutant." Unexpectedly, DICER1 mutations as well as all other defining tumor mutations (TP53 mutations and RAS-pathway mutations) were not inherited in all 19 patients where analyzation was possible. These tumors have an aggressive clinical course. Multimodal combination therapy based on surgery, ifosfamide, carboplatin, and etoposide chemotherapy, and local radiotherapy leads to superior outcomes.
Substances chimiques
DICER1 protein, human
EC 3.1.26.3
Ribonuclease III
EC 3.1.26.3
DEAD-box RNA Helicases
EC 3.6.4.13
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
697-707Subventions
Organisme : Damp-Foundation
ID : 2014-09
Organisme : Fördergemeinschaft Kinderkrebszentrum Hamburg
Informations de copyright
© 2021 American Cancer Society.
Références
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803-820.
Tomita T, Gonzalez-Crussi F. Intracranial primary nonlymphomatous sarcomas in children: Experience with eight cases and review of the literature. Neurosurgery. 1984;14:529-540.
Merimsky O, Lepechoux C, Terrier P, Vanel D, Delord JP, LeCesne A. Primary sarcomas of the central nervous system. Oncology. 2000;58:210-214. doi:10.1159/00001210
Benesch M, von Bueren AO, Dantonello T, et al. Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups. J Neurooncol. 2012;111:337-345. doi:10.1007/s11060-012-1020-3
Maher OM, Khatua S, Mukherjee D, et al. Primary intracranial soft tissue sarcomas in children, adolescents, and young adults: single institution experience and review of the literature. J Neurooncol. 2016;127:155-163. doi:10.1007/s11060-015-2027-3
Lafay-Cousin L, Lindzon G, Taylor MD, et al. Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children. J Neurosurg Pediatr. 2016;17:298-302. doi:10.3171/2015.6.peds14709
de Kock L, Priest JR, Foulkes WD, Alexandrescu S. An update on the central nervous system manifestations of DICER1 syndrome. Acta Neuropathol. 2020;139:689-701. doi:10.1007/s00401-019-01997-y
Koelsche C, Mynarek M, Schrimpf D, et al. Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathol. 2018;136:327-337. doi:10.1007/s00401-018-1871-6
Lee JC, Villanueva-Meyer JE, Ferris SP, et al. Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. Acta Neuropathol. 2019;137:521-525. doi:10.1007/s00401-019-01960-x
McCluggage WG, Foulkes WD. DICER1-associated sarcomas: towards a unified nomenclature. Mod Pathol. 2021;34:1226-1228. doi:10.1038/s41379-020-0602-4
Kamihara J, Paulson V, Breen MA, et al. DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020;33:1910-1921. doi:10.1038/s41379-020-0516-1
Sakaguchi M, Nakano Y, Honda-Kitahara M, et al. Two cases of primary supratentorial intracranial rhabdomyosarcoma with DICER1 mutation which may belong to a “spindle cell sarcoma with rhabdomyosarcoma-like feature, DICER1 mutant.” Brain Tumor Pathol. 2019;36:174-182. doi:10.1007/s10014-019-00352-z
de Kock L, Geoffrion D, Rivera B, et al. Multiple DICER1-related tumors in a child with a large interstitial 14q32 deletion. Genes Chromosomes Cancer. 2018;57:223-230. doi:10.1002/gcc.22523
Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555:469-474. doi:10.1038/nature26000
Sahm F, Schrimpf D, Jones DT, et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2016;131:903-910. doi:10.1007/s00401-015-1519-8
Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164. doi:10.1093/nar/gkq603
Kopanos C, Tsiolkas V, Kouris A, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35:1978-1980. doi:10.1093/bioinformatics/bty897
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-424. doi:10.1038/gim.2015.30
Molho-Pessach V, Schaffer JV. Blaschko lines and other patterns of cutaneous mosaicism. Clin Dermatol. 2011;29:205-225. doi:10.1016/j.clindermatol.2010.09.012
Koelsche C, Schrimpf D, Stichel D, et al. Sarcoma classification by DNA methylation profiling. Nat Commun. 2021;12:498. doi:10.1038/s41467-020-20603-4
Castellanos E, Rosas I, Negro A, et al. Mutational spectrum by phenotype: panel-based NGS testing of patients with clinical suspicion of RASopathy and children with multiple cafe-au-lait macules. Clin Genet. 2020;97:264-275. doi:10.1111/cge.13649
Digilio MC, Lepri F, Baban A, et al. RASopathies: clinical diagnosis in the first year of life. Mol Syndromol. 2011;1:282-289. doi:10.1159/000331266
Oliveira AM, Scheithauer BW, Salomao DR, Parisi JE, Burger PC, Nascimento AG. Primary sarcomas of the brain and spinal cord: a study of 18 cases. Am J Surg Pathol. 2002;26:1056-1063. doi:10.1097/01.PAS.0000020481.56467.D2
Al-Gahtany M, Shroff M, Bouffet E, et al. Primary central nervous system sarcomas in children: clinical, radiological, and pathological features. Child Nerv Syst. 2003;19:808-817. doi:10.1007/s00381-003-0839-5
Tihan T, Griffin A, Ozuysal S. Primary sarcomas of the central nervous system: UCSF experience. (1985-2005). Turk J Pathol. 2007;23:5-15.
Ferrari A, Dirksen U, Bielack S. Sarcomas of soft tissue and bone. Prog Tumor Res. 2016;43:128-141. doi:10.1159/000447083